Friday, February 17, 2017

Paradigm Diagnostics Finds $7M

Phoenix-based Paradigm Diagnostics, a developer of diagnostic test for cancer tumor sequencing, has raised $7M in a Series B funding round, the company said Thursday. The company said it closed it round with an additional $3M from New Science Ventures, which came on top of an earlier $3.5M from Mesa Verde Venture Partners. The company said the funds goes towards accelerating commercial adoption of its cancer diagnostic tests. Dr. Grace Colon of New Science Ventures joins the company's board with the funding.